LONDON–(BUSINESS WIRE)–Medical hashish R&D firm, Kanabo Group Plc, immediately introduced that it has appointed Dr Dan Poulter MP as a Non-Government Director to the board. As each a former UK Authorities well being minister, and because the chairperson of the All-Celebration Parliamentary Group for World Well being, Dr Poulter has an in depth data of the medication and medicines regulatory framework within the UK. His mix of medical, governmental, and healthcare coverage expertise makes him properly positioned to assist Kanabo’s mission to determine and lead a regulated medicinal hashish market within the UK and Europe.
Dr Poulter is a training NHS Psychiatrist who believes that prescribed hashish merchandise may convey appreciable well being advantages to assist individuals experiencing psychological ailing well being and misery. He has beforehand been concerned in advocating medical hashish for the advantage of sufferers by his work on a lot of medical and coverage our bodies.
Avihu Tamir, CEO, Kanabo Group, stated, “We’re delighted to welcome Dr Dan Poulter, MP as a Non-Government Director to our board. Dan brings a wealth of information and perception into the enterprise that strengthens our group as we construct a medicinal hashish market within the UK and Europe.”
Dr Poulter stated, “As a physician, I’m more and more conscious of the potential of cannabis-based medicines. Hashish merchandise are quick turning into obtainable that would ship vital enhancements to the lives of 1000’s of sufferers affected by situations starting from persistent ache to submit traumatic stress dysfunction.
Kanabo is a longtime chief in medical hashish analysis and innovation. As such, the corporate is creating a brand new commonplace within the trade by offering higher and safer entry to such hashish medicines. I’m happy to have the ability to lend my data and expertise to the corporate’s work on this crucially essential endeavour.”
Chairman of the Board, David Tsur, added: “We’re delighted that Dr Dan Poulter has joined us and we’d prefer to warmly welcome him. He brings a wealth of expertise and I’m positive can be a really worthwhile addition to the Board. It’s an thrilling interval for Kanabo to execute the corporate’s marketing strategy and to develop its exercise and strategic partnerships.”
ABOUT KANABO GROUP PLC:
Kanabo is an trade chief in product improvement and commercialisation of each cannabis-derived merchandise for medical sufferers and THC-free merchandise for CBD shoppers. It develops high-quality medical hashish extract formulation, medical machine vaporisers, and different revolutionary supply strategies. Validation actions are carried out at Kanabo’s analysis lab on the Weizmann Science Park in Israel. With a major deal with the German and UK Markets, Kanabo has already begun penetrating the European Market, and is positioned to scale as much as meet rising market demand and projected gross sales. Presently, Kanabo is promoting its line of CBD formulation for inhalation within the UK and Germany and has agreements with distributors within the pharmaceutical and OTC sectors already in place.